Licensing

Our specialist healthcare team, with backgrounds in the life sciences, understand the complexities of valuations and deal structures that are unique to licensing deals in pharma and biotech and are with our clients every step of the way.

We support clients with:

- In-licensing
- Out-licensing
- Drug licensing
- Facility licensing

Our Latest Deals

Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Feb 2022
has received investment from
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has received investment from
Nov 2021
has invested in
company name confidential

Results. Great people creating great outcomes, together.

Latest Insights

Corporate News
3rd August 2022

We are joining forces with Canaccord Genuity

We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market.  This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you. […]

Insights
27th July 2022

Transforming healthcare with real-world evidence (RWE)

The healthcare industry experienced a revolutionary shift when it switched from practising medicine as an art to evidence-based medicine, which is based on relatively simple randomised clinical trials to determine which treatment option was safe and effective. Through the years, evidence-based medicine became the gold standard for clinical development. However, this method has become less […]

Reports
19th July 2022

The Technology Services Perspective – Q2 2022

H1 2022 deal volumes have increased significantly across the board, up 37% over H1 2021. Strategic M&A continues to drive this quarter’s deal activity, namely acquiring footholds in near/offshore hotspots, vendor-specific tech stacks (particularly AWS, Salesforce and SAP) and or next-gen capabilities, such as conversational AI and data analytics. Public tech companies broadly tracked the […]